3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
4
Recruiting
3
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
57
Myelodysplastic Syndromes
33
Leukemia, Myelomonocytic, Chronic
16
Leukemia
15
Recurrence
8
Multiple Myeloma
8
Neoplasms
6
Primary Myelofibrosis
5
Myeloproliferative Disorders
5
Lymphoma, Non-Hodgkin
5
Hematologic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasm Metastasis
3
Lymphoma, Follicular
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms, Plasma Cell
2
Neoplasm, Residual
2
Lymphoma, Mantle-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Myeloid
2
Hodgkin Disease
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Anemia, Refractory, with Excess of Blasts
2
Interventions
Cyclophosphamide
9
fludarabine phosphate
7
Cyclosporine
7
Peripheral Blood Stem Cell Transplantation
6
Mycophenolic Acid
6
Busulfan
6
Tacrolimus
5
Radiotherapy
5
Methotrexate
5
Antilymphocyte Serum
5
Filgrastim
4
Cord Blood Stem Cell Transplantation
4
Sirolimus
3
Methylprednisolone
3
Melphalan
3
Rituximab
2
Moxifloxacin
2
Flow Cytometry
2
Etoposide
2
Cytarabine
2
Arsenic Trioxide
2
Alemtuzumab
2
venetoclax
1
trametinib
1
ruxolitinib
1
regorafenib
1
ponatinib
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Myelodysplastic-Myeloproliferative Diseases
×
Azacitidine
×
Clear all
NCT05609942
2025-04-10
AZURE
Blueprint Medicines Corporation
Phase 1
Terminated
9 enrolled